Caladrius Biosciences Inc Stock Nasdaq
Equities
US1280581042
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-20 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
05-20 | Lisata Therapeutics Receives European Medicines Agency Pediatric Waiver for Pancreatic Cancer Treatment | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 25.92M 35.4M |
---|---|---|---|---|---|
Net income 2024 * | -25M -34.14M | Net income 2025 * | -30M -40.97M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.01
x | P/E ratio 2025 * |
-1.16
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.21% |
Latest transcript on Caladrius Biosciences Inc
1st Jan change | Capi. | |
---|---|---|
+52.36% | 58.06B | |
-3.86% | 40.53B | |
+36.84% | 38.99B | |
-12.01% | 26.56B | |
+14.13% | 26.7B | |
-21.62% | 18.98B | |
+0.21% | 12.17B | |
+25.96% | 11.92B | |
+23.02% | 12B |